

**2026 World Conference
on Lung Cancer**

SEPTEMBER 12 – 15, 2026 | SEOUL, REPUBLIC OF KOREA

ICI-Induced Hypercoagulability in NSCLC - Clinical Validation and Mechanistic Insight

Dr. HaoYi Jin
China

How to validate the ICI-induced hypercoagulability in NSCLC ?


12-month cumulative incidence of VTE

Healthy population 0.4%

Cancer patients 3.4%


Cancer patients+ICI 11.1%

NSCLC patients+ICI 12.5%




CoagScore Pipeline

A




B




microthrombus + microthrombus -


HE




IHC (GPIb)



PTAH




What is the clinical significance of ICI-induced hypercoagulability ?




What is the mechanism underlying ICI-induced hypercoagulability ?


A F3 Expression: treatment naive vs post treatment




B




C




D




E



F





Thank You.